Table 3.
Estimated Hazard Ratiosa for Exacerbation Risk (Cox Model and Base Joint Model, Study A)
| Parameter | Hazard Ratio (95% CI) | |||
|---|---|---|---|---|
| Cox Proportional Hazards Model | Joint Model | |||
| Formoterol DPI 9 µg | 0.85 | (0.69–1.07) | 0.89 | (0.71–1.12) |
| Budesonide/formoterol pMDI 160/9 µg | 0.71 | (0.56–0.89) | 0.76 | (0.60–0.95) |
| Budesonide/formoterol pMDI 320/9 µg | 0.65 | (0.51–0.81) | 0.69 | (0.55–0.87) |
| Baseline FEV1 association coefficient, increase per 100 mL | 0.92 | (0.90–0.94) | 0.92 | (0.89–0.94) |
| Longitudinal ∆FEV1 association coefficient, increase per 100 mL | 0.91 | (0.86–0.96) | ||
Notes: aDerived from point estimates. Estimates for country not shown. For a full summary of parameters, see the Supplementary Material.
Abbreviations: CI, confidence interval; DPI, dry powder inhaler; FEV1, forced expiratory volume in 1 second; ∆FEV1, change from baseline in forced expiratory volume in 1 second; mL, milliliter; pMDI, pressurized metered dose inhaler.